Spruce Biosciences to Participate in the Jefferies Healthcare Conference
24 Mai 2023 - 10:05PM
Business Wire
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
biopharmaceutical company focused on developing and commercializing
novel therapies for rare endocrine disorders with significant unmet
medical need, today announced that Javier Szwarcberg, M.D., M.P.H.,
Chief Executive Officer, will present at the Jefferies Healthcare
Conference on June 9, 2023, at 9:30 a.m. ET.
Interested parties can access the live webcast here. An archived
copy of the webcast will be available on the events section of the
company’s investor relations website for approximately 30 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company
focused on developing and commercializing novel therapies for rare
endocrine disorders with significant unmet medical need. Spruce is
initially developing its wholly-owned product candidate,
tildacerfont, as the potential first non-steroidal therapy for
patients suffering from classic congenital adrenal hyperplasia
(CAH). Spruce is also developing tildacerfont for women suffering
from polycystic ovary syndrome (PCOS) with primary adrenal androgen
excess. To learn more, visit www.sprucebiosciences.com and follow
us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230524005174/en/
Media Contact Will Zasadny Evoke Canale (619) 961-8848
will.zasadny@evokecanale.com media@sprucebio.com
Investors Xuan Yang Solebury Strategic Communications
(415) 971-9412 xyang@soleburystrat.com investors@sprucebio.com
Spruce Biosciences (NASDAQ:SPRB)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Spruce Biosciences (NASDAQ:SPRB)
Historical Stock Chart
Von Jan 2024 bis Jan 2025